Wet Age-Related Macular Degeneration

AbbVie and Regenxbio have entered into a partnership to develop and commercialize RGX-314, an investigational gene therapy, for the treatment of retinal diseases, according to a press release.

A phase 2 trial investigating an 8 mg dose of aflibercept revealed no new safety signals compared with aflibercept 2 mg in patients with wet age-related macular degeneration, according to a press release from Regeneron Pharmaceuticals.

The American Academy of Ophthalmology has asked CMS and HHS to prohibit Medicare Advantage and exchange plans from suggesting biosimilar alternatives to Avastin, according to a press release.

ONS-5010 demonstrated statistically significant results in the treatment of patients with wet age-related macular degeneration, according to a press release from Outlook Therapeutics.

The FDA has accepted Genentech’s biologics license application under priority review for faricimab to treat neovascular age-related macular degeneration and diabetic macular edema.

In a video interview, Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institute, associate professor of ophthalmology at Lerner College of Medicine and Healio/OSN Board Member, discusses exploring gene therapy in intermediate and advanced stages of dry AMD.

In a video interview, Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institute, associate professor of ophthalmology at Lerner College of Medicine and Healio/OSN Board Member, discusses medication delivery options, such as port delivery system and using antibiotic prophylaxis.

In a video interview, Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institute, associate professor of ophthalmology at Lerner College of Medicine and Healio/OSN Board Member, discusses treating patients in real-world clinical practice, with a focus on vitamin therapy to prevent progression in dry AMD and a treat-and-extend approach for wet AMD.

In a video interview, Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institute, associate professor of ophthalmology at Lerner College of Medicine and Healio/OSN Board Member, discusses the greatest areas of unmet need, including needing other mechanisms of action to inhibit for treatment of wet AMD and addressing the progression of geographic atrophy in dry AMD.

WAILEA, Hawaii — In this video from Hawaiian Eye, Jay S. Duker, MD, chief strategic scientific officer at EyePoint, discusses the development of a long-acting, sustained release, bio-erodible implant for the treatment of retinal disease.